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Abstract
Background:  The metallo-β -lactamases are Zn(II)-containing enzymes that hydrolyze the β -
lactam bond in penicillins, cephalosporins, and carbapenems and are involved in bacterial antibiotic
resistance. There are at least 20 distinct organisms that produce a metallo-β -lactamase, and these
enzymes have been extensively studied using X-ray crystallographic, computational, kinetic, and
inhibition studies; however, much is still unknown about how substrates bind and the catalytic
mechanism. In an effort to probe substrate binding to metallo-β -lactamase L1 from
Stenotrophomonas maltophilia, nine site-directed mutants of L1 were prepared and characterized
using metal analyses, CD spectroscopy, and pre-steady state and steady state kinetics.
Results:  Site-directed mutations were generated of amino acids previously predicted to be
important in substrate binding. Steady-state kinetic studies using the mutant enzymes and 9
different substrates demonstrated varying Km and kcat values for the different enzymes and
substrates and that no direct correlation between Km and the effect of the mutation on substrate
binding could be drawn. Stopped-flow fluorescence studies using nitrocefin as the substrate showed
that only the S224D and Y228A mutants exhibited weaker nitrocefin binding.
Conclusions: The data presented herein indicate that Ser224, Ile164, Phe158, Tyr228, and Asn233
are not essential for tight binding of substrate to metallo-β -lactamase L1. The results in this work
also show that Km values are not reliable for showing substrate binding, and there is no correlation
between substrate binding and the amount of reaction intermediate formed during the reaction.
This work represents the first experimental testing of one of the computational models of the
metallo-β -lactamases.
Background
The overuse of antibiotics in the clinic and for agricultural
uses has resulted in a tremendous selective pressure for
antibiotic resistant bacteria. These bacteria become resist-
ant by a number of mechanisms, such as producing en-
zymes that hydrolyze or inactivate the antibiotics,
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producing efflux pumps that transport the antibiotic out
of the cell, or modifying their cell wall components so
they no longer bind effectively to the antibiotics [1–3].
The most common, least expensive, and effective antibiot-
ics are the β -lactam containing antibiotics, such as the
penicillins, cephalosporins, and carbapenems [2,4,5].
These antibiotics are mechanism-based inhibitors of
transpeptidase, a bacterial enzyme required for the pro-
duction of a strong viable cell wall [6,7]. In response to
the widespread use of β -lactam containing antibiotics,
bacteria have acquired the ability to produce β -lactama-
ses, which are enzymes that hydrolyze and inactivate β -
lactam containing antibiotics. There are over 300 distinct
β -lactamases known, and these enzymes have been
grouped by a number of classification schemes [8–15].
For example, Bush has developed a scheme, based on the
enzymes' molecular properties, that has four distinct β -
lactamase groups [10,15]. One of the more alarming
groups are the Bush group 3 enzymes, which are Zn(II)
dependent enzymes that hydrolyze nearly all known β -
lactam containing antibiotics and for which there are no
or very few known clinical inhibitors [9,14,16–19]. The
metallo-β -lactamases have been further divided by Bush
into subgroups based on amino acid sequence identity:
the Ba enzymes share a >23% sequence identity, require 2
Zn(II) ions for full activity, prefer penicillins and cepha-
losporins as substrates, and are represented by metallo-β -
lactamase CcrA from Bacteroides fragilis, the Bb enzymes
share a 11% sequence identity with the Ba enzymes, re-
quire only 1 Zn(II) ion for full activity, prefer carbapen-
ems as substrates, and are represented by the metallo-β -
lactamase imiS from Aeromonas sobria, and the Bc enzymes
have only 9 conserved residues with the other metallo-β -
lactamases, require 2 Zn(II) ions for activity, contain a dif-
ferent metal binding motif than the other metallo-β -lacta-
mases, prefer penicillins as substrates, and are represented
by the metallo-β -lactamase L1 from Stenotrophomonas mal-
tophilia[9]. A similar grouping scheme (B1, B2, and B3)
based on structural properties of the metallo-β -lactamases
has recently been offered [41]. The diversity of the group
3 β -lactamases is best exemplified by the enzymes' vastly
differing efficacies towards non-clinical inhibitors; these
differences predict that one inhibitor may not inhibit all
metallo-β -lactamases [18,20–29]. To combat this prob-
lem, we are characterizing a metallo-β -lactamase from
each of the subgroups in an effort to identify a common
structural or mechanistic aspect of the enzymes that can
be targeted for the generation of an inhibitor. It is hoped
that this inhibitor, when given in combination with an ex-
isting antibiotic, will prove to be an effective therapy
against bacteria that produce a metallo-β -lactamase. This
work describes our efforts on metallo-β -lactamase L1
from S. maltophilia.
S. maltophilia is an important pathogen in nosocomial in-
fections of immunocompromised patients suffering from
cancer, cystic fibrosis, drug addition, AIDS and in patients
with organ transplants and on dialysis [30–32]. This or-
ganism is inherently resistant to most antibiotics due to its
low outer membrane permeability [33] and to β -lactam
containing antibiotics due to the production of a chromo-
somally expressed group 2e β -lactamase (L2) and a group
3c β -lactamase (L1) [34,35]. L1 has been cloned, over-ex-
pressed, and partially characterized by kinetic and crystal-
lographic studies [36,37]. The enzyme exists as a
homotetramer of ca. 118 kDa in solution and in the crys-
talline state. The enzyme tightly binds two Zn(II) ions per
subunit and requires both Zn(II) ions for full catalytic ac-
tivity. The Zn1 site has 3 histidine residues and 1 bridging
hydroxide as ligands, and the Zn2 site has 2 histidines, 1
aspartic acid, 1 terminally-bound water, and the bridging
hydroxide as ligands. Spencer and coworkers used the
crystal structure and modeling studies to propose a sub-
strate binding model and identified several active site res-
idues that were involved in substrate binding (Figure 1)
[37]. However, this model has not been tested experimen-
tally. In order to prepare tight binding inhibitors of the
metallo-β -lactamases, knowledge about how substrate
binds to the enzymes is needed so that all substrate-en-
zyme binding contacts can be maintained in any pro-
posed inhibitor. This work describes our efforts at
understanding how substrates bind to metallo-β -lacta-
mase L1. Several site-directed mutants of L1 were generat-
ed and characterized, and the results from these studies
reveal that none of the active site residues predicted from
earlier computational studies [37] are essential for tight
substrate binding.
Results
Wild type L1
Wild-type L1 was over-expressed in Escherichia coli and pu-
rified as previously described [36]. This procedure pro-
duced an average of 50–60 mg of >90% pure, active
protein per 4 L of growth culture. Circular dichroism spec-
tra were collected on wild-type samples to ensure L1 ex-
pressed using the pET26b expression system had the
correct secondary structure. The CD spectrum of wild type
L1 showed an intense, broad feature at 190 nm and a
smaller feature at 215 nm (see Additional file 1: CD spec-
tra). These features are consistent with a sample with sig-
nificant  α /β  content. The Compton and Johnson
algorithm [38] was used to estimate secondary structure in
the samples; wild-type L1 was estimated to have 38.3% α -
helix, 26.7% β -structure (9.3% antiparallel β -sheet, 2.1%
parallel  β -sheet, and 15.3% β -turn), and 34.9% other
structure. These estimates are in excellent agreement with
the crystallographically determined secondary structure of
~40% α -helix and 30% β -structure [37]. Metal analyses on
multiple preparations of wild-type L1 demonstrated thatBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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the enzyme binds 1.9 ± 0.2 Zn(II) ions per monomer (Ta-
ble 2), in agreement with previous results [36].
Steady state kinetic studies were performed on multiple
preparations of wild type L1, and the resulting kinetic data
are shown in Tables 3,4,5. When using nitrocefin as sub-
strate and 50 mM cacodylate, pH 7.0, as buffer, wild-type
L1 exhibited a kcat value of 38 ± 1 s-1 and a Km value of 12
± 1 µM. The inclusion of 100 µM ZnCl2 in the assay buffer
resulted in slightly lower values of Km and higher values
for  kcat[36]. The inclusion of higher concentrations of
Zn(II) did not further affect the steady-state kinetic con-
stants. Apparently, the purified, recombinant enzyme
does not bind its full complement of Zn(II); therefore,
100  µM Zn(II) was included in all subsequent kinetic
studies.
Wild-type L1 exhibited kcat values of 41 ± 1 s-1, 1.9 ± 0.1
s-1, 42 ± 1 s-1, and 82 ± 5 s-1 for the cephalosporins, ni-
trocefin, cefoxitin, cefaclor, and cephalothin. For these
same substrates, the Km values were 4 ± 1 µM, 1.1 ± 0.1
µM, 13 ± 1 µM, and 8.9 ± 1.5 µM, respectively. Two peni-
cillins were tested as substrates, and penicillin G and amp-
icillin exhibited Km values of 38 ± 12 µM and 55 ± 5 µM
and kcat values of 600 ± 100 s-1 and 520 ± 10 s-1, respec-
tively (Table 4). Three carbapenems were also used as sub-
strates for L1, and biapenem, imipenem, and meropenem
exhibited Km values of 32 ± 1 µM, 57 ± 7 µM, and 15 ± 4
µM and kcat values of 134 ± 4 s-1, 370 ± 5 s-1, and 157 ± 9
s-1, respectively (Table 5). L1's preference for penicillins
and carbapenems over cephalosporins, as exemplified by
the kcat values, is in agreement with previous studies and
supports L1's placement in the β -lactamase 3c family [9].
Rapid-scanning visible spectra of 25 µM wild-type L1 with
5 µM nitrocefin demonstrated a decrease in absorbance at
390 nm, an increase at 485 nm, and a rapid increase and
slower decrease in absorbance at 665 nm. These spectra
are similar to those previously reported for wild-type L1
and nitrocefin [39], and the features can be attributed to
substrate decay, product formation, and intermediate for-
mation and decay, respectively. Under these conditions,
2.2 µM intermediate was formed during the first 10 milli-
seconds of the reaction (Figure 2), and the rate of decay of
this intermediate corresponds to the steady-state kcat (Ta-
ble 3). To probe further the binding of nitrocefin to wild-
type L1, stopped-flow fluorescence studies were conduct-
ed as previously described [40] (Figure 3). The reaction of
wild-type L1 with nitrocefin under steady-state conditions
at 10°C resulted in a rapid decrease in fluorescence fol-
lowed by a rate-limiting return of fluorescence (Figure
3A). Fitting of the data, as described by Spencer et al.[40],
resulted in a KS value for wild-type L1 of 38 ± 5 µM (Figure
3B).
Figure 1
Active site residues that were mutated in this study. Figure
was rendered using Rasmol v. 2.6. The coordinates were
obtained from the Protein Data Bank using the accession
number 1 sml.
Table 1: Oligonucleotides used in preparation of L1 mutants
Primer Sequence
pUCMSZFor CTATgCggCATCAgAgCAgATT
M13Rev gATAACAATTTCACACAggA
Y228AFor CTgAgTgCACCgggCgCCCAgCTgCAgggAAAC
Y228ARev gTTTCCCTgCAgCTgggCgCCCggTgCACTCAg
Y228FFor CTgAgTgCACCgggCTTCCAgCTgCAgggAAAC
Y228FRev gTTTCCCTgCAgCTggAAgCCCggTgCACTCAg
S224DFor TACgCCgACAgCCTggACgCACCgggCTACCAg
S224DRev CAggTAgCCCggTgCgTCCAggCTgTCggCgTA
S224AFor TACgCCgACAgCCTggCCgCACCgggCTACCAg
S224ARev CAggTAgCCCggTgCggCCAggCTgTCggCgTA
S224KFor TACgCCgACAgCCTgAAggCACCgggCTACCAg
S224KRev CAggTAgCCCggTgCCTCCAggCTgTCggCgTA
F158AFor AgCgATgACCTgCACgCCggCgATggCATCACC
F158ARev ggTgATgCCATCgCCggCgTgCAggTCATCgCT
I164AFor CACTTCggCgATggCgCCACCTACCCgCCTgCC
I164ARev ggCAggCgggTAggTggCgCCATCgCCgAAgTg
N233LFor TACCAgCTgCAgggACTgCCCCgTTATCCgCAC
N233LRev gTgCggATAACggggCAgTCCCTgCAgCTggTA
N233DFor TACCAgCTgCAgggAgACCCCCgTTATCCgCAC
N233DRev gTgCggATAACgggggTCTCCCTgCAgCTggTABMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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Ser224 mutants
(the BBL numbering scheme proposed in reference 41 was
used throughout this manuscript). All sequenced subclass
Ba and Bb metallo-β -lactamases (except VIM-1) have a
lysine residue at position 224 [41], and all computational
models for substrate binding to the metallo-β -lactamases
assume that the invariant carboxylate on substrates forms
an electrostatic interaction with this lysine. In L1, the res-
idue at position 224 is a serine [35], and the substrate-
binding model for L1 predicts that this serine residue in-
teracts with the carboxylate on substrate via a water mole-
cule [37]. To test the proposed role of Ser224 in L1, serine
was changed to an alanine (S224A), aspartic acid
(S224D), and lysine (S224K), and these mutants were
characterized using metal analyses, CD spectroscopy,
steady-state kinetics, and pre-steady state kinetic studies.
Small-scale growth cultures showed that all three mutants
were over-expressed at levels comparable to those of wild-
type L1. Large-scale over-expression and purification of
the mutants showed that all three mutants were isolatable
at levels comparable to those of wild-type L1. Metal anal-
yses of the S224A and S224D mutants showed that both
mutants bind nearly two Zn(II) ions (Table 2), like wild-
type L1 [36]; however, the S224K mutant binds only 1.0
Zn(II) per protein. CD spectra of the mutants were similar
to those of wild-type L1 (see Figure in Additional materi-
als). Steady-state kinetic studies were conducted with all
three mutants in buffer containing 100 µM ZnCl2 to en-
sure that both Zn(II) binding sites were saturated in these
studies. Addition of higher concentrations of Zn(II) did
not result in different values for the steady-state kinetic
constants in Tables 3,4,5.
When the cephalosporins were used as substrates, the
S224A and S224K mutants exhibited 2- to 4-fold changes
in Km values (Table 3). In studies with cefoxitin, cefaclor,
and cephalothin as substrate, the observed kcat values for
the S224A and S224K mutants were 2- to 7-fold lower;
however, the kcat values when using nitrocefin as substrate
were slightly higher (< 2-fold). On the other hand, the
S224D mutant exhibited 3- to 50-fold higher Km values
and 2- to 20-fold lower kcat values for the cephalosporins
tested. A similar trend was observed in kinetic studies
when using penicillins as substrates (Table 4). Generally,
the S224A and S224K mutants exhibited small changes in
Km and kcat, while the S224D mutant yielded 20- to 40-
fold increased values for Km and >10-fold decreases in kcat
when using the penicillins as substrates. When the carbap-
enems were used as substrates however, the changes in Km
values were relatively smaller than with the other sub-
strates, and 2- to 37-fold changes in kcat were observed
(Table 5).
Rapid-scanning Vis studies of the S224X mutants were
conducted to probe whether the mutations caused chang-
es in the amount of intermediate that accumulates during
catalysis. When 50 µM S224A was reacted with 5 µM ni-
Figure 2
Intermediate formation by wild-type L1 and L1 mutants. The
spectra were collected using rapid scanning Vis studies, and
the absorbance values at 668 nm were converted to concen-
tration values as described in Materials and Methods. Typical
reactions were conducted with 25 µM L1 (or mutant) and 5
µM nitrocefin in 50 mM cacodylate, pH 7.0, containing 100
µM ZnCl2 at 25°C.
Table 2: Metal Content of Wild-type L1 and L1 mutants
Sample Zn(II) Content (moles Zn(II)/
mole of enzyme)a
Wild-type 1.9 ± 0.2
S224A 1.8 ± 0.2
S224D 1.7 ± 0.3
S224K 1.0 ± 0.1
Y228A 1.8 ± 0.1
Y228F 1.7 ± 0.3
F158A 1.5 ± 0.2
I164A 1.6 ± 0.2
N233L 1.8 ± 0.2
N233D 1.5 ± 0.1
a The final dialysis buffer was used as a blank, and the Zn(II) content in 
the final dialysis buffers was shown to be < 0.5 µM in separate ICP 
measurements.B
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Table 3: Steady-state kinetic constants for hydrolysis of cephalosporins by wild-type L1 and L1 mutants.
nitrocefin cefoxitin cefaclor cephalothin
Enzyme Km (µM) kcat (s-1) kcat/Km ×  
107 M-1 s-1
Km (µM) kcat (s-1) kcat/Km ×  
107 M-1 s-1
Km (µM) kcat (s-1) kcat/Km ×  107 M-1 s-1 Km (µM) kcat (s-1) kcat/Km ×  
10-7 M-1 s-1
w.t. 4 ± 14 1  ± 11 . 0 1 . 1  ± 0.1 1.9 ± 0.1 0.17 13 ± 14 2  ± 1 0.32 8.9 ± 1.5 82 ± 50 . 9 2
S224A 7 ± 14 8  ± 5 0.69 3.0 + 0.5 1.0 ± 0.1 0.033 14 ± 21 4  ± 1 0.10 3.6 ± 0.1 19.8 ± 0.2 0.55
S224K 14 ± 2 48 ± 10 0.34 2.0 ± 0.3 0.60 ± 0.06 0.030 13 ± 26 . 5  ± 0.3 0.050 6.2 ± 0.6 26 ± 10 . 4 2
S224D 11 ± 52 . 3  ± 0.4 0.021 50 ± 61 . 4  ± 0.2 0.0028 215 ± 17 3 ± 1 0.0014 75 ± 7 32 ± 20 . 0 4 3
I164A 8 ± 21 3 0  ± 30 1.6 11 ± 18  ± 1 0.073 3.3 + 0.5 30 ± 30 . 9 11 6  ± 11 4 6  ± 20 . 9 1
F158A 123 ± 20 1290 ± 20 1.0 11 ± 21 6  ± 2 0.15 135 ± 23 99 ± 9 0.073 63 ± 17 353 ± 35 0.56
Y228A 23 ± 37 2  ± 2 0.31 10 ± 25 . 8  ± 0.3 0.058 550 ± 100 40 ± 3 0.0073 290 ± 60 320 ± 40 0.11
Y228F 36 ± 16 81 ± 18 0.23 8.2 ± 1.1 5.5 ± 0.5 0.067 240 + 60 74 ± 40 . 0 3 15 8  ± 7 190 ± 50 0.33
N233L 7 ± 2 62 ± 12 0.89 4.4 ± 1.6 0.90 ± 0.17 0.020 14± 23 2  ± 1 0.23 8.0 + 0.7 51 ± 10 . 6 4
N233D 9 ± 22 1  ± 2 0.23 1.1 ± 0.2 1.1 ± 0.1 0.10 25 ± 53 4  ± 30 . 1 41 8  ± 4 65 ± 20 . 3 6
Table 4: Steady-state kinetic constants for hydrolysis of penicillins by wild-type L1 and L1 mutants.
pencilin G ampicillin
Enzyme Km (µM) kcat (s-1) kcat/Km ×  107 Km (µM) kcat (s-1) kcat/Km ×  107
w.t. 38 ± 12 600 ± 100 1.6 55 ± 5 520 ± 10 0.95
S224A 70 ± 20 580 ± 100 0.83 125 ± 13 339 ± 10 . 2 7
S224K 44 ± 8 124 ± 12 0.28 25 ± 31 5 2  ± 20 . 6 1
S224D 1600 ± 200 42 ± 9 0.0026 1100 ± 240 10 ± 1 0.00091
I164A 60 ± 5 698 ± 100 1.2 43 ± 3 524 ± 100 1.2
F158A 50 ± 5 138 ± 10 0.28 165 ± 20 270 ± 30 0.16
Y228A 410 ± 60 609 ± 64 0.15 710 ± 74 443 ± 10 0.062
Y228F 140 ± 14 630 ± 30 0.45 271 ± 40 243 ± 30 0.090
N233L 33 ± 9 184 ± 35 0.56 90 ± 20 508 ± 40 0.56
N233D 60 ± 2 440 ± 86 0.73 117 ± 18 621 ± 31 0.53
Table 5: Steady-state kinetic constants for hydrolysis of carbapenems by wild-type L1 and L1 mutants
biapenem imipenem meropenem
Enzyme Km (µM) kcat (s-1) kcat/Km ×  107 Km (µM) kcat (s-1) kcat/Km ×  107 Km (µM) kcat (s-1) kcat/Km ×  107
w.t. 32 ± 1 134 ± 40 . 4 2 5 7  ± 73 7 0  ± 50 . 6 5 1 5  ± 41 5 7  ± 91 . 0
S224A 34 ± 55 6  ± 20 . 1 62 9  ± 41 0 0  ± 30 . 3 45 0  ± 10 244 ± 10 . 4 9
S224K 100 ± 22 43 ± 2 0.043 60 ± 4 14 ± 1 0.023 12 ± 12 1 2  ± 11 . 8
S224D 64 ± 72 2  ± 1 0.034 42 ± 4 17 ± 1 0.040 132 ± 23 69 ± 70 . 0 5 2
I164A 55 ± 3 112 ± 1 0.20 92 ± 11 570 ± 43 0.62 14 ± 1 96 ± 30 . 6 9
F158A 50 ± 11 70 ± 50 . 1 4 1 0 0  ± 20 370 ± 50 0.37 7 ± 2 36 ± 20 . 5 1
Y228A 175 ± 25 21 ± 2 0.012 350 ± 94 134 ± 36 0.038 4.5 ± 0.2 26 ± 10 . 5 8
Y228F 150 ± 23 51 ± 4 0.034 107 ± 13 83 ± 10 0.078 13 ± 1 70 ± 10 . 5 4
N233L 29 ± 3 105 ± 60 . 3 6 3 6  ± 5 250 ± 20 0.69 12 ± 1 67 ± 30 . 5 6
N233D 28 ± 87  ± 1 0.025 71 ± 16 158 ± 13 0.22 16 ± 43 . 5  ± 0.1 0.022BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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trocefin, 1.7 µM intermediate formed during the first 10
milliseconds of the reaction (Figure 2), and rate of decay
of this intermediate was equal to the steady-state kcat (Ta-
ble 3). In spite of utilizing a number of reaction condi-
tions, the S224K and S224D mutants yielded rapid-scan
spectra with no detectable absorbances at 665 nm (Figure
2), indicating that the intermediate is not stabilized as
well in these mutants as in wild-type L1. Stopped-flow flu-
orescence studies at 10°C with the S224A, S224D, and
S224K mutants and nitrocefin as the substrate resulted in
KS values of 39 ± 10, 213 ± 63, and 33 ± 5 µM, respective-
ly.
Asn233 mutants
Two-thirds of all sequenced metallo-β -lactamases have an
Asn at position 233 [41], and this residue was predicted
[42] and shown [43] to be involved with substrate bind-
ing and activation by interacting electrostatically with the
substrate β -lactam carbonyl. However, in L1, Asn233 is 14
Å away from the modeled position of the substrate β -
lactam carbonyl [37]. To test the role of Asn233 in sub-
strate binding, the Asn was changed to a leucine (N233L)
and to an aspartic acid (N233D), and these mutants were
characterized by using metal analyses, CD spectroscopy,
steady-state kinetics, and pre-steady state kinetic studies.
Small-scale growth cultures showed that both mutants
were over-expressed at levels comparable to that of wild-
type L1. Large-scale over-expression and purification of
the mutants showed that both mutants were isolatable at
levels comparable to that of wild-type L1. Metal analyses
of the N233L and N233D mutants showed that both bind
nearly two Zn(II) ions (Table 2), like wild-type L1 [36].
CD spectra of the mutants were similar to those of wild-
type L1. Steady-state kinetic studies were conducted with
both mutants in buffer containing 100 µM ZnCl2 to en-
sure that both Zn(II) binding sites were saturated in these
studies. Addition of higher concentrations of Zn(II) did
not result in different values for the steady-state kinetic
constants in Tables 3,4,5.
With all substrates tested, the N233L and N233D mutants
exhibited Km values that differed less than a factor of 4
than that observed for wild-type L1 (Tables 3,4,5). The kcat
values exhibited by these mutants for all substrates also
differed by less than a factor of 4, except when biapenem
and meropenem were used as substrates for the N233D
mutant. With these two substrates, there was a 19-fold
and 45-fold decrease in the kcat values when using biapen-
em and meropenem, respectively (Table 5). The steady-
state kinetic data generally support the prediction that
Asn233 does not play a large role in binding or catalysis.
However, rapid-scanning Vis studies of N233L and
N233D with nitrocefin demonstrate that no detectable
amounts of intermediate are formed during the reaction,
even when using a wide number of reaction conditions
(Figure 2). Stopped-flow fluorescence studies at 10°C with
the N233L and N233D mutants and nitrocefin as sub-
strate resulted in KS values of 26 ± 9 and 25 ± 8 µM, respec-
tively.
Tyr228 mutants
The substrate-binding model showed that Tyr228 in L1
was position-conserved with Asn233 in the other crystal-
lographically characterized metallo-β -lactamases
[37,42,44–46]. Spencer and coworkers postulated that
Figure 3
(A) Stopped-flow fluorescence of wild-type L1 with nitroce-
fin. In a typical reaction, 5–10 µM wild-type L1 was mixed
with various concentrations of nitrocefin, and the reaction
was monitored for up to 1 second at 10°C, using the condi-
tions described in Materials and Methods. The data were fit-
ted to a double exponential using SigmaPlot v. 6.10.(B) Plot
of observed rate constant versus concentration of nitrocefin.
Solid lines were fitted to the data as described in Materials
and Methods.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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Tyr228 is part of an oxyanion hole that interacts with the
β -lactam carbonyl on substrate and helps to stabilize the
putative tetrahedral intermediate formed during substrate
turnover [37]. To test this hypothesis, Tyr228 was changed
to an alanine and to a phenylalanine to afford the Y228A
and Y228F mutants, respectively.
Small-scale growth cultures showed that both mutants
were over-expressed at levels comparable to those of wild-
type L1. Large-scale over-expression and purification of
the Y228A and Y228F mutants showed that both mutants
were isolatable at levels comparable to those of wild-type
L1. Metal analyses of the mutants showed that both bind
nearly two Zn(II) ions (Table 2), like wild-type L1 [36],
and CD spectra of the mutants were similar to those of
wild-type L1. Steady-state kinetic studies were conducted
with both mutants in buffer containing 100 µM ZnCl2 to
ensure that both Zn(II) binding sites were saturated in
these studies. Addition of higher concentrations of Zn(II)
did not result in different values for the steady-state kinet-
ic constants in Tables 3,4,5.
When cephalosporins were used as substrates, the Y228A
and Y228F mutants exhibited Km values that were 6- to
45-fold higher than those observed for wild-type L1 (Ta-
ble 3). The largest change in Km was observed when ce-
faclor was used as substrate, and the smallest change was
observed when nitrocefin was used as substrate. The
Tyr228 mutants exhibited < 4-fold change in kcat values
for the cephalosporins tested (Table 3), suggesting that
Tyr228 is not playing a large role in catalysis. When peni-
cillins were used as substrates, the Tyr228 mutants exhib-
ited 3- to 13-fold increased Km values and < 2-fold
changes in kcat, as compared to the values ascertained us-
ing wild-type L1 (Table 4). On the other hand when car-
bapenems were used as substrates, the Tyr228 mutants
exhibited < 6-fold increases in Km values as compared to
those values for wild-type L1 (Table 5). Interestingly, there
was a 2- to 8-fold drop in kcat values for the Tyr228 mu-
tants, as compared to values observed for wild-type L1,
when using the carbapenems as substrates.
Rapid-scanning Vis spectra of the reaction of the Y228A
and Y228F mutants with nitrocefin demonstrated a
marked decrease in the amount of intermediate formed
with these mutants (Figure 2). In reactions with 50 µM
mutant and 5 µM nitrocefin, only 0.75 and < 0.30 µM in-
termediate formed for the Y228F and Y228A mutants, re-
spectively. The concentration of mutants were varied
between 25 to 150 µM to ensure that all of the substrate
was bound; however, none of the reactions resulted in the
detection of intermediate at levels observed for wild-type
L1 (data not shown). Stopped-flow fluorescence studies at
10°C of nitrocefin hydrolysis by Y191A and Y191F result-
ed in KS values of 85 ± 9 and 22 ± 6 µM, respectively.
Ile164 and Phe158 mutants
All crystallographically characterized metallo-β -lactama-
ses have a flexible amino acid chain that extends over the
active site [37,42,44–49]. Previous NMR studies on CcrA
have shown that this loop "clamps down" on substrate or
inhibitor upon binding, and there is speculation that the
distortion of substrate upon clamping down of the loop
may drive catalysis [50]. The crystal structure of L1
showed that there is a large loop that extends over the ac-
tive site, and modeling studies have predicted that two res-
idues, Ile164 and Phe158, make significant contacts with
large, hydrophobic substituents at the 2' or 6' positions on
penicillins, cephalosporins, or carbapenems [37]. To test
this prediction, Ile 164 and Phe158 were changed from
large, hydrophobic residues to alanines to afford the
I164A and F158A mutants.
Small-scale growth cultures demonstrated the I164A and
F158A mutants were over-expressed at levels comparable
to that of wild-type L1 (data not shown). Large-scale over-
expression and purification of the mutants resulted in
comparable quantities of isolatable enzymes, which had
identical CD spectra as wild-type L1 and bound slightly
less Zn(II) than wild-type L1 (Table 2). All steady-state ki-
netic studies were conducted in buffers containing 100
µM ZnCl2 to ensure that both metal binding sites were sat-
urated during the studies.
When using the cephalosporins, nitrocefin, cefoxitin, and
cephalothin, as substrates and the I164A mutant, there
were 2- to 10-fold (only for cefoxitin) increases in Km and
2- to 4-fold increases in kcat observed (Table 3). However
when cefaclor was used as substrate, the I164A mutant ex-
hibited a 3-fold decrease in Km and a 1.5-fold decrease in
kcat (Table 3). On the other hand, the Km and kcat values
for the I164A mutant when the penicillins or carbapen-
ems were used as substrates were very similar to those
numbers exhibited by wild-type L1 (Tables 4 and 5).
When the cephalosporins were used as substrates for the
F158A mutant, the Km values observed were 7- to 31-fold
higher than those determined for wild-type L1, and sur-
prisingly, the kcat values were 2- to 31-fold higher than
those exhibited by wild-type L1 (Table 3). As with the
I164A mutant, the changes in Km and kcat for the penicil-
lins and carbapenems were relatively small, as compared
with the values obtained with the cephalosporins (Table
4).
Rapid-scanning Vis studies on nitrocefin hydrolysis by
I164A and F158A showed a marked decrease in interme-
diate accumulation, with the I164A mutant generating <
0.30 µM intermediate and the F158A producing no detect-
able intermediate (Figure 2). Stopped-flow fluorescence
studies at 10°C resulted in a KS value of 31 ± 11 µM for theBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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I164A mutant. The reaction of F158A with nitrocefin was
so rapid, we could not determine a KS value for this mu-
tant.
Discussion
β -Lactam containing antibiotics constitute the largest class
of antibiotics, and these compounds are relatively inex-
pensive to produce, cause minor side effects, and are effec-
tive towards a number of bacterial strains. Nonetheless,
bacterial resistance to these antibiotics is extensive, most
commonly due to the bacterial production of β -lactama-
ses [10,51]. In fact, there have been over 300 distinct β -
lactamases reported, and most of these enzymes utilize an
active site serine group to nucleophilically attack the β -
lactam carbonyl, resulting in a hydrolyzed product that is
covalently attached to the active site. To combat these en-
zymes, β -lactamase inhibitors such as clavulanic acid, sul-
bactam, and tazobactam have been given in combination
with a β -lactam containing antibiotic to treat bacterial in-
fections [52]. One class of β -lactamases that are particular-
ly unaffected by the known β -lactamase inhibitors and
have been shown to hydrolyze almost all known β -lactam
containing antibiotics including late generation carbapen-
ems at high rates are the metallo-β -lactamases [14–19].
Although there are no reports of metallo-β -lactamases iso-
lated from major pathogens [51,53], these enzymes are
produced by pathogens such as B. fragilis, S. maltophilia,
and P. aeruginosa. It is inevitable that the continued and
extensive use of β -lactam antibiotics will result in a major
pathogen that produces a metallo-β -lactamase.
Efforts to solve the crystal structure of one of the metallo-
β -lactamases with a bound substrate molecule have failed,
most likely due to the high activity of the enzymes to-
wards all β -lactam containing antibiotics [37,54]. There-
fore, computational studies have been used extensively to
study substrate binding, the role of the Zn(II) ions in ca-
talysis, the protonation state of the active site, and inhibi-
tor binding [37,42,55–59]. All of the substrate binding
models have made assumptions before the substrate was
docked into the active site [37,42], and some of these as-
sumptions have been shown to be invalid for certain sub-
strates [43]. With L1, two key assumptions were made: (1)
the bridging hydroxide functions as the nucleophile dur-
ing catalysis and (2) Zn1 coordinates the β -lactam carbo-
nyl [37]. With these assumptions and after energy
minimizations, Ser224 was predicted to hydrogen bond
to the substrate carboxylate [37], reminiscent of the role
predicted for Lys224 in CcrA [42]. Ullah et al. predicted
that Phe158 and Ile 164 form hydrophobic interactions
with bulky substituents on the substrate, suggesting that
the loss of these residues would only affect binding of sub-
strates with large aromatic substituents [37]. In the mode-
ling studies on CcrA [42], Asn233 was predicted to
interact with the β -lactam carbonyl on substrate, and mu-
tagenesis studies have supported this prediction [43]. Al-
though Asn233 is sequence conserved in L1[35], it is
located 14Å away from the modeled position of the β -
lactam carbonyl and was predicted not to play a role in
substrate binding to L1[37]. On the other hand, the sub-
strate-binding model predicted that Tyr228 was in posi-
tion to offer a hydrogen bond to the β -lactam carbonyl
and participate in an oxyanion hole that was proposed to
form as the substrate was hydrolyzed [37]. By using the
crystal structure and modeling studies on L1, Ullah et al.
proposed a reaction mechanism for the enzyme [37]. To
test this proposed mechanism and the proposed roles of
the amino acids discussed above, site-directed mutagene-
sis studies were conducted on metallo-β -lactamase L1 and
reported herein.
The overlap extension method [60] was used to prepare
the site-directed mutants, and a variety of studies were
used to probe whether the single point mutations resulted
in large structural changes in the mutant enzymes. (1) The
over-expression levels of mutants were analyzed with
SDS-PAGE to ensure that the mutations did not result in
changes in the over-expression levels of the enzymes.
With a few L1 mutants and with other enzyme systems in
the lab, single point mutations often result in depressed
levels of over-expression [61]. In the case of the mutants
described here, all of the mutants over-expressed at levels
comparable to wild-type L1 (data not shown). (2) The to-
tal amounts of the mutants isolatable after chromatogra-
phy were compared with wild-type L1 levels. We have
found, in particular with metal binding mutants of L1 (G.
Periyannan, R.B. Yates, and M.W. Crowder, unpublished
results) and glyoxalase II [61], that single point mutations
can result in over-expressed mutants being processed into
inclusion bodies and unisolatable as soluble proteins. In
the case of the mutants described here, all of the mutants
were isolated at levels comparable to wild-type L1. (3) CD
spectra were collected for all mutants and compared to the
spectrum of wild-type L1. Although we did not expect a
large change in the secondary structure of L1 upon single
point mutations, CD spectroscopy is the most common
structural technique to characterize site-directed mutants.
All of the mutants described here exhibited CD spectra
that were very similar, or identical, to that of wild-type L1
(see Additional file 1: CD spectra). (4) Metal analyses on
the mutants were used to probe whether point mutations
caused a significant change to the metal binding site as to
preclude metal binding. The crystal structures of the met-
allo-β -lactamases reveal a complex and far-reaching hy-
drogen-bonding network around the metal binding sites,
and disruption of this network is predicted to affect metal
binding [37,42,44,45,48,49,62,63]. With all of the mu-
tants described here except the S224K mutant, each mu-
tant binds wild-type or near-wild-type levels of Zn(II)
after purification. The S224K mutant exhibited a 50% re-BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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duction in metal binding (Table 2), and we postulate this
is due to electrostatic repulsions between the newly intro-
duced Lys with Zn2. In spite of the mutants binding signif-
icant amounts of Zn(II), we included 100 µM ZnCl2 in all
of the kinetic buffers to ensure saturation of the metal
binding sites and to facilitate direct comparison of the ki-
netic data. (5) All mutants were stable to multiple freeze/
thaw cycles and to prolonged storage (> 3 weeks) at 4°C,
retaining > 95% of their activity. With these five lines of
evidence, we were confident that none of the point muta-
tions resulted in large structural changes in L1 and that
any kinetic differences could be attributed to the changed
amino acid.
As a first approximation of substrate binding, we exam-
ined the steady-state kinetics of 4 cephalosporins, 2 peni-
cillins, and 3 carbapenems (Tables 3,4,5) and compared
the Km values of the mutants with those of wild-type L1.
The substrates tested were chosen because they exhibited
low Km values in previous kinetic studies [36], and we be-
lieved that we could saturate the enzymes with substrate
even if there was large change in binding with the point
mutations. The Tyr228 mutants exhibited increased Km
values for 8 of the 9 substrates tested, with the smallest
changes in Km observed when the carbapenems were used
as the substrate. This result supports the proposed role of
Tyr228 in substrate binding. In contrast, the results on the
Ser224 mutants suggest that this residue is not important
in substrate binding, since the S224A and S224K mutants
did not exhibit any significant increases (by a factor of ≥
10) in Km for any of the substrates tested. Only when
Ser224 was replaced with an Asp residue was there signif-
icant increases in the observed Km value for 6 of the 9 sub-
strates tested, and the largest changes were exhibited when
the penicillins were used as substrates. This result sup-
ports the observation of differential binding modes of
substrates to the β -lactamases, depending on the structure
of the substrate [43,64,65]. The only remaining mutants
that exhibited significant changes in the Km values were
the I164A and F158A mutants. The I164A mutant exhibit-
ed increased Km values only when using cefoxitin as the
substrate, suggesting an interaction of the isoleucine
group with the methoxy group on cefoxitin. The F158A
mutant exhibited higher Km values when using the cepha-
losporins as substrates, suggesting an interaction of the ce-
phalosporins' substituents with the phenylalanine on the
loop that extends over the active site. None of the other
mutants exhibited vastly different values for Km with any
of the substrates tested.
An examination of the kcat values of the mutants revealed
some surprising results. The S224D mutants displayed de-
creased kcat values for 7 of the 9 substrates tested. Since
similar results were not observed with the S224K and
S224A mutants, we do not propose a catalytic role for
Ser224. Instead, we predict that the insertion of an aspar-
tic acid into the active site at position 224 results in a
change in the hydrogen bonding network in L1; this hy-
drogen bonding network is extensive in all metallo-β -
lactamases that have been characterized crystallographi-
cally [37,42,44,45,48,49,62,63]. The N233D mutant also
exhibited greatly reduced kcat values for biapenem and
meropenem but not for imipenem or any of the other sub-
strates tested. This mutation is also predicted to affect the
hydrogen bonding network around the active site, and ap-
parently, interactions of the enzyme with the 4' substitu-
ent of the carbapenems has an effect on catalysis. More
surprisingly are the increases in kcat of the F158A mutants.
We are uncertain why the mutation of residues on the
loop that extends over the active site would affect kcat,
since substrate and product binding have been predicted
to be very fast in the reaction of nitrocefin with L1. How-
ever, we do note that the kcat/Km values of wild-type L1
and F158A differ by a factor less than 2.
The inability to propose a consistent binding model also
supports the recent proposal that different substrates of L1
are hydrolyzed by different mechanisms and further sug-
gests that using steady-state kinetic constants may not be
a valid way to probe substrate binding to L1. In addition,
the minimal kinetic mechanism of nitrocefin hydrolysis
by L1 has been reported, and this mechanism predicts that
Km does not accurately reflect substrate binding. By using
this mechanism [39], Km is equal to {(k-1 + k2)k3k4} /
{k1(k3k4 + k2k4 + k2k3}. To probe more directly the reac-
tion, stopped-flow absorbance studies were conducted,
and the substrate decay rates (390 nm) were studied as a
function of nitrocefin concentration. While nitrocefin is a
nontypical substrate, as a result of the dinitro-substituted
styryl substituent [40], it is the substrate about which the
most is known about its hydrolysis mechanism. There-
fore, kinetic studies with nitrocefin as substrate allowed
for us to evaluate the effect of point mutations on the re-
action mechanism of L1. There was no clear dependence
on substrate decay rates with nitrocefin concentration (da-
ta not shown). We did note though that the amount of in-
termediate formed during the reactions varied
considerably depending upon which mutant of L1 was
used in the study. All of the mutants exhibited decreases
in intermediate formation, and the S224D, S224K, F158A,
N233D, and N233L mutants yielded rapid-scanning data
consistent with no detectable intermediate. These same
mutants exhibited vastly differing Km values. Clearly there
is no correlation of Km with the presence of the reaction
intermediate. Apparently, the ability to observe the inter-
mediate is not governed entirely by the choice of substrate
[40], and it also depends on precise arrangement of active
site residues. It is also possible that the site-directed mu-
tants could be utilizing a different mechanism to hydro-
lyze nitrocefin [66].BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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Recently, Spencer and co-workers reported that stopped-
flow fluorescence studies can be used to monitor the reac-
tion of L1 with nitrocefin and that an initial binding step
can be directly monitored [40]. By increasing the concen-
tration of nitrocefin, the rate of the initial binding step in-
creased to a maximum, and fitting of these data yielded a
binding constant (called KS herein) for nitrocefin. Each of
the L1 mutants were studied using the stopped-flow fluo-
rescence studies, and the resulting data were fitted as re-
ported by Spencer et al.[40] (Table 6). All of the mutants
exhibited KS values identical, within error, to wild-type
L1, except the S224D and the Y228A mutants. The place-
ment of a negative charge at position 224 drastically af-
fects nitrocefin binding and results in a 6-fold decrease in
binding affinity (Table 6). To a lesser degree, the aromatic
portion of Tyr228 must have an effect on the binding site
as the KS value for nitrocefin binding to this mutant is de-
creased by a factor of 2; however, the hydroxyl group
probably does not form a hydrogen bond to the substrate
as proposed. By using nitrocefin as substrate and Km val-
ues alone, a completely different conclusion is reached re-
garding important substrate binding residues. The results
presented here suggests that none of the residues in this
study are essential for tight nitrocefin binding, possibly
because other parts of the active site accommodate the
loss of certain binding contacts.
Spencer  et al. also reported stopped-flow fluorescence
studies when using cefaclor and meropenem as substrates,
and KS values for these substrates were reported to be 710
± 180 and 272 ± 112 µM, respectively [40]. However in
our hands, the rates of substrate hydrolysis were so fast
when using wild-type L1 that we could not use substrate
concentrations high enough to saturate the enzyme. Sim-
ilarly, we could not determine KS values for penicillin G or
ampicillin because the observed rates of hydrolysis at low
substrate concentrations were too fast to observe data,
even at 10°C.
Conclusions
The results presented herein indicate that none of the ac-
tive site residues identified with computational studies are
essential for tight substrate binding. These data also indi-
cate that the use of Km values to describe substrate binding
to L1 is unreliable and that there is no correlation between
intermediate accumulation and substrate binding affinity.
These results demonstrate that new computational studies
are now needed to probe substrate binding to L1, and
these studies are currently underway. The results present-
ed herein can be used to guide these new computational
studies, which will lead to the design of potential inhibi-
tors and hopefully a way to combat penicillin resistance in
bacteria.
Materials and Methods
Materials
E. coli strains DH5α  and BL21(DE3) pLysS were obtained
from Gibco BRL and Novagen, respectively. Plasmids
pET26b and pUC19 were purchased from Novagen. Prim-
ers for sequencing and mutagenesis studies were pur-
chased from Integrated DNA Technologies.
Deoxynucleotide triphosphates (dNTP's), MgSO4, ther-
mopol buffer, Deep Vent DNA polymerase, and restric-
tions enzymes were purchased from Promega or New
England Biolabs. Polymerase chain reaction was conduct-
ed using a Thermolyne Amplitron II unit. DNA was puri-
fied using the Qiagen QIAQuick gel extraction kit or
Plasmid Purification kit with QIAGEN-tip 100 (Midi) col-
umns. Wizard Plus Minipreps were acquired from Prome-
ga. Luria-Bertani (LB) media was made following
published procedures [67]. Isopropyl-β -thiogalactoside
(IPTG), Biotech grade, was procured from Anatrace. Phe-
nylmethylsulfonylfluoride (PMSF) was purchased from
Sigma. Protein solutions were concentrated with an Ami-
con ultrafiltration cell equipped with YM-10 DIAFLO
membranes from Amicon, Inc. Dialysis tubing was pre-
pared using Spectra/Por regenerated cellulose molecular
porous membranes with a molecular weight cut-off of 6–
8,000 g/mol. Q-Sepharose Fast Flow was purchased from
Amersham Pharmacia Biotech. Nitrocefin was purchased
from Becton Dickinson, and solutions of nitrocefin were
filtered through a Fisherbrand 0.45 micron syringe filter.
Cefaclor, cefoxitin, and cephalothin were purchased from
Sigma; penicillin G and ampicillin were purchased from
Fisher. Imipenem, meropenem, and biapenem were gen-
erously supplied by Merck, Zeneca Pharmaceuticals, and
Lederle (Japan), respectively. All buffers and media were
prepared using Barnstead NANOpure ultrapure water.
Table 6: Km and KS values for Wild-type L1 and mutants with ni-
trocefin as substrate
Enzyme Km (µM) KS (µM)
Wild-type 4 ± 13 8  ± 5
S224A 7 ± 1 39 ± 10
S224D 11 ± 52 1 3  ± 63
S224K 14 ± 23 3  ± 5
F158A 4 ± 1N . D .
I164A 8 ± 2 31 ± 11
Y228A 23 ± 38 5  ± 9
Y228F 36 ± 16 22 ± 6
N233D 9 ± 22 6  ± 8
N233L 7 ± 22 5  ± 7
N.D. – not determinedBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/4
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Generation of site-directed mutants of L1
The over-expression plasmid for L1, pUB5832, was digest-
ed with NdeI and HindIII, and the resulting ca. 900 bp
piece was gel purified and ligated using T4 ligase into
pUC19, which was also digested with NdeI and HindIII, to
yield the cloning plasmid pL1PUC19. Mutations were in-
troduced into the L1 gene by using the overlap extension
method of Ho et al.[60], as described previously [68]. The
oligonucleotides used for the preparation of the mutants
are shown in Table 1. The ca. 900 bp PCR products were
digested with NdeI and HindIII and ligated into pUC19.
The DNA sequences were analyzed by the Biosynthesis
and Sequencing Facility in the Department of Biological
Chemistry at Johns Hopkins University. After confirma-
tion of the sequence, the mutated pL1PUC19 plasmid was
digested with NdeI and HindIII, and the 900 bp, mutated
L1 gene was gel purified and ligated into pET26b to create
the mutant overexpression plasmids. To test for overex-
pression of the mutant enzymes, E. coli BL21(DE3)pLysS
cells were transformed with the mutated over-expression
plasmids, and small scale growth cultures were used [68].
Large-scale (4 L) preparations of the L1 mutants were per-
formed as described previously [36]. Protein purity was
ascertained by SDS-PAGE.
Metal content
The concentrations of L1 and the mutants were deter-
mined by measuring the proteins' absorbance at 280 nm
and using the published extinction coefficient of ε 280 nm
= 54,804 M-1•cm-1[36] or by using the method of Pace
[69]. Before metal analyses, the protein samples were dia-
lyzed versus 3 ×  1 L of metal-free, 50 mM HEPES, pH 7.5
over 96 hours at 4°C. A Varian Inductively Coupled Plas-
ma Spectrometer with atomic emission spectroscopy de-
tection (ICP-AES) was used to determine metal content of
multiple preparations of wild type L1 and L1 mutants.
Calibration curves were based on three standards and had
correlation coefficient limits of at least 0.9950. The final
dialysis buffer was used as a blank, and the Zn(II) content
in the final dialysis buffers was shown to be < 0.5 µM (de-
tection limit of ICP) in separate ICP measurements. The
emission line of 213.856 nm is the most intense for zinc
and was used to determine the Zn content in the samples.
The errors in metal content data reflect the standard devi-
ation (σ n-1) of multiple enzyme preparations.
Steady-state kinetic studies
Steady-state kinetic assays were conducted at 25°C in 50
mM cacodylate buffer, pH 7.0, containing 100 µM ZnCl2
on a HP 5480A diode array UV-Vis spectrophotometer at
25°C. The changes in molar absorptivities (∆ε ) used to
quantitate products were (in M-1cm-1): nitrocefin, ∆ε 485 =
17,420; cephalothin, ∆ε 265= -8,790; cefoxitin, ∆ε 265= -
7,000; cefaclor, ∆ε 280= -6,410; imipenem, ∆ε 300= -9,000;
meropenem,  ∆ε 293= -7,600; biapenem, ∆ε 293= -8,630;
ampicillin, ∆ε 235= -809; and penicillin G, ∆ε 235 = -936.
When possible, substrate concentrations were varied be-
tween 0.1 to 10 times the Km value. In kinetic studies us-
ing substrates with low Km values (cefoxitin, nitrocefin,
and cephalothin) or with small ∆ε  values (penicillin and
ampicillin), we typically used substrate concentrations
varied between ~ Km and 10 ×  Km and used as much of the
∆ A versus time data (that was linear) as possible to deter-
mine the velocity. Steady-state kinetics constants, Km and
kcat, were determined by fitting initial velocity versus sub-
strate concentration data directly to the Michaelis equa-
tion using CurveFit [36]. The reported errors reflect fitting
uncertainties. All steady-state kinetic studies were per-
formed in triplicate with recombinant L1 from at least
three different enzyme preparations.
Circular dichroism
Circular dichroism samples were prepared by dialyzing
the purified enzyme samples versus 3 ×  2 L of 5 mM phos-
phate buffer, pH 7.0 over six hours. The samples were di-
luted with final dialysis buffer to ~75 µg/mL. A JASCO J-
810 CD spectropolarimeter operating at 25°C was used to
collect CD spectra.
Stopped – flow/Rapid-Scanning UV-Visible Spectropho-
tometry
Rapid-scanning Vis spectra of nitrocefin hydrolysis by L1
and the L1 mutants were collected on a Applied Photo-
physics SX.18MV stopped-flow spectrophotometer
equipped with an Applied Photophysics PD.l photodiode
array detector and a 1 cm pathlength optical cell. A typical
experiment consisted of 25 µM enzyme and 5 µM nitroce-
fin in 50 mM cacodylate buffer, pH 7.0 containing 100
µM ZnCl2, the reaction temperature was thermostated at
25°C, and the spectra were collected between 300 and 725
nm. Data from at least three experiments were collected
and averaged. Absorbance data were converted to concen-
tration data as described previously by McMannus and
Crowder [39]. Stopped-flow fluorescence studies of ni-
trocefin hydrolysis by L1 were performed on an Applied
Photophysics SX.18MV spectrophotometer, using an exci-
tation wavelength of 295 nm and a WG320 nm cut-off fil-
ter on the photomultiplier. These experiments were
conducted at 10°C using the same buffer in the rapid-
scanning Vis studies. Fluorescence data were fitted to kobs
= {(kf [S]) / KS + [S])} + kr as described previously [40] or
to kobs = kf [S] + kr by using CurveFit v. 1.0.
Abbreviations
AES, atomic emission spectroscopy; bp, base pairs; CD,
circular dichroism; ε , extinction coefficient; ICP, induc-
tively coupled plasma; kcat, turnover number; kDa, kilo-
daltons; Km, Michaelis constant; KS, substrate binding
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